 "Claris Lifesciences surges on USFDA nod for Tobramycin injection")
Claris Lifesciences rallied 13% to Rs 246 in early morning trade on the BSE after the company said that it has received the Abbreviated New Drug Application (ANDA) approval for Tobramycin Injection USP, 80mg/2mL and 1,200mg/30mL multiple dose vials, in the US.
“Tobramycin Injection is an anti-infective used to treat certain serious infections that are caused by bacteria such as meningitis and other infections of the blood, abdomen (stomach area), lungs, skin, bones, joints, and urinary tract,” Claris Lifesciences said in a press release.
The estimated market size in the US is $6 million, as the product is currently in shortage list of the US dug regulator, US Food and Drug Administration (USFDA), it added.
Claris expects more product approvals during the year, which will allow it to continue its growth in the US market.
At 09:21 AM, the stock was up 9% at Rs 237 on the BSE. Around 88,000 shares changed hands on the counter against an average sub 50,000 shares that were traded daily in past two weeks on the BSE.
“Tobramycin Injection is an anti-infective used to treat certain serious infections that are caused by bacteria such as meningitis and other infections of the blood, abdomen (stomach area), lungs, skin, bones, joints, and urinary tract,” Claris Lifesciences said in a press release.
The estimated market size in the US is $6 million, as the product is currently in shortage list of the US dug regulator, US Food and Drug Administration (USFDA), it added.
Claris expects more product approvals during the year, which will allow it to continue its growth in the US market.
At 09:21 AM, the stock was up 9% at Rs 237 on the BSE. Around 88,000 shares changed hands on the counter against an average sub 50,000 shares that were traded daily in past two weeks on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%